Rimonabant

• CAT Number: I002198
• CAS Number: 168273-06-1
• Molecular Formula: C22H21Cl3N4O
• Molecular Weight: 463.80
• Purity: ≥95%
• Synonyms: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
• Target: Cannabinoid Receptor
• Solubility: DMSO 25 mg/mL; Water <1 mg/mL
• Storage: 3 years -20C powder
• IC50: 1.8 nM(Ki)
• InChI: InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
• InChIKey: JZCPYUJPEARBJL-UHFFFAOYSA-N
• SMILES: CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl

Rimonabant（Cat No.:I002198）is a selective cannabinoid receptor type 1 (CB1) antagonist that was developed to treat obesity and related metabolic disorders. By blocking CB1 receptors in the brain, Rimonabant reduces appetite and promotes weight loss. It also showed potential for improving lipid profiles and insulin sensitivity, making it useful for managing cardiovascular risks associated with obesity and type 2 diabetes. However, due to concerns over psychiatric side effects, including depression and anxiety, Rimonabant was withdrawn from the market, although it remains a significant compound in cannabinoid receptor research.

Reference

[1]. Leite, C.E., Mocelin, C.A., Petersen, G.O., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61 217-224 (2009).
[2]. Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268.
[3]. Heppenstall C, Bunce S, Smith JC. Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant. Nutr J. 2012 Jul 23;11(1):50.
[4]. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):905-15.
[5]. Mandhane S, Nayak P, Soni D, Jain S, Ashton JC, Rajamannar T. Induction of glucose intolerance by acute administration of rimonabant. Pharmacology. 2012;89(5-6):339-47.